Efficacy and Safety of Third-generation EGFR-TKI Combined With Anlotinib as Maintenance Therapy Following 4-6 Cycles of Chemotherapy and Immunotherapy in NSCLC With Small Cell Transformation After EGFR-TKI Resistance: a Single-arm Prospective Phase II Study
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2024 New trial record